80 dopamine release in the NAc25. The adapta- Environmental factors. Environmental factors
tions in this pathway seem to be involved in the that have been consistently associated with
relapse that occurs after drug withdrawal in the propensity to self-administer drugs
70
animals previously trained to self-administer a include low socio-economic class, poor
drug when they are again exposed to the drug, parental support and drug availability. Stress
60 a drug stimulus or stress25. might be a common feature in a wide variety
At the circuit level, there is clear evidence of environmental factors that increase the risk
that adaptations in the mesocortical circuit for drug abuse. The mechanisms responsible
50 (including the OFC and CG) cause compulsive for stress-induced increases in vulnerability to
Percent of initiates
drug administration and poor inhibitory drug use and to relapse in people who are
control, and they probably participate in addicted are not yet well understood, but
40
relapse. However, adaptations also seem to there is evidence that the stress-responsive
occur in the mesolimbic circuit (including the neuropeptide corticotropin-releasing factor is
30 NAc, amygdala and hippocampus), which involved through its effects in the amygdala
probably cause the enhanced saliency value of and the pituitary–adrenal axis35.
the drug and drug stimuli, and the decreased Imaging techniques now allow us to
20
sensitivity to natural reinforcers26. Further- investigate how environmental factors affect
more, adaptations have also been reported in the brain and how these, in turn, affect the
10
the nigrostriatal circuit (including the dorsal behavioural responses to drugs of abuse. For
striatum), which might underlie habits that example, in non-human primates, social
are linked to the rituals of drug consumption27. status affects D2-receptor expression in the
0
Child Teen Young Adult
brain, which in turn affects the propensity for
<12 12–17 adult >25 Vulnerability to addiction cocaine self-administration36. Animals that
18–25 Genetic factors. It is estimated that 40–60% of achieve a dominant status in the group show
Figure 2 | Age at which marijuana use is first the vulnerability to addiction is attributable to increased numbers of D2 receptors and are
initiated. Data from the National Survey of Drug genetic factors28. In animal studies, several reluctant to administer cocaine, whereas
Use and Health57. genes have been identified that are involved animals that are subordinate have lower
in drug responses, and their experimental D2-receptor numbers and readily administer
modifications markedly affect drug self- cocaine. As animal studies have shown that
in the enhanced incentive motivational value administration29. In humans, several chromo- increasing D2 receptors in NAc markedly
of the drug (a process that results in increased somal regions have been linked to drug abuse, decreases drug consumption (which has been
‘wanting’ in contrast to just ‘liking’ the drug) but only a few specific genes have been identi- shown for alcohol37), this could provide a
in the addicted person23. fied with polymorphisms (alleles) that either mechanism by which a social stressor could
At the neurotransmitter level, addiction- predispose to or protect from drug addiction28. modify the propensity to self-administer
related adaptations have been documented Some of these polymorphisms interfere with drugs.
not only for dopamine, but also for glutamate, drug metabolism. For example, specific alleles
GABA, opiates, serotonin and various neuro- for the genes that encode alcohol dehydroge- Co-morbidity with mental illness. The risk
peptides. These changes contribute to the nases ADH1B and ALDH2 (enzymes involved for substance abuse and addiction in individ-
abnormal function of brain circuits. For in the metabolism of alcohol) are reportedly uals with mental illness is significantly higher
example, in individuals who are addicted to protective against alcoholism30. Similarly, than for the general population. The high
cocaine, imaging studies have documented polymorphisms in the gene that encodes co-morbidity probably reflects, in part, over-
that disrupted dopamine activity in the brain cytochrome P-450 2A6 (an enzyme that is lapping environmental, genetic and neuro-
(shown by reductions in dopamine D2 re- involved in nicotine metabolism) are report- biological factors that influence drug abuse
ceptors) is associated with abnormal activity edly protective against nicotine addiction31. and mental illness38.
in the orbitofrontal cortex (OFC) and in the Furthermore, genetic polymorphisms in the It is likely that different neurobiological
anterior cingulate gyrus (CG) — brain regions cytochrome P-450 2D6 gene (an enzyme that factors are involved in co-morbidity depend-
that are involved in salience attribution and is involved in conversion of codeine to mor- ing on the temporal course of its develop-
inhibitory control24 (FIG. 3). Abnormal function phine) seem to provide a degree of protection ment (that is, mental illness followed by drug
of these cortical regions has been particularly against codeine abuse 32. abuse or vice versa). In some instances, the
revealing in furthering our understanding of Some polymorphisms in receptor genes mental illness and addiction seem to co-
addiction , as their disruption is linked to that mediate drug effects have also been occur independently39, but in others there
compulsive behaviour (OFC) and disinhibi- associated with a higher risk of addiction. For might be a sequential dependency. It has
tion24 (CG). Therefore, the abnormalities in example, there is an association between been proposed that co-morbidity might be
these frontal regions could underlie the com- alcoholism and the genes for the GABA type A due to the use of the abused drugs to self-
pulsive nature of drug administration in (GABAA) receptors GABRG3 (REF. 33) and medicate the mental illness in cases in which
addicted individuals and their inability to con- GABRA2 (REF. 34). D2-receptor polymorphisms the onset of mental illness is followed by
trol their urges to take the drug when they are have been linked to a higher vulnerability to abuse of some types of drug. But, when
exposed to it. In addition, animal studies have drug addiction, although some studies have drug abuse is followed by mental illness, the
shown that drug-related adaptations in these failed to replicate this finding28. Replication of chronic exposure could lead to neurobiologi-
frontal regions result in enhanced activity many of the genetic findings in substance cal changes, which might explain the increased
in the glutamatergic pathway that regulates abuse and addiction is still pending. risk of mental illness38. For example, the high
a Dopamine D2 receptors c lives when they are more likely to take risks,
70
Orbitofrontal cortex (OFC) interventions that educate them about the
65 harmful effects of drugs with age-appropriate
messages can decrease the rate of drug use44,45.
(micromol/100g/min)
60
However, not all media campaigns and
Metabolism
55
school-based educational programmes have
50
been successful46. Tailored interventions that
45
take into account socio-economic, cultural,
40 age and gender characteristics of children and
35 adolescents are more likely to improve the
30
effectiveness of the interventions.
Control Cocaine abuser 1.5 2 2.5 3 3.5 4 4.5 At present, prevention strategies include
D2-receptor availability not only educational interventions based on
b Brain glucose metabolism
70 comprehensive school-based programmes and
Cingulate gyrus (CG) effective media campaigns and strategies that
65
decrease access to drugs and alcohol, but also
(micromol/100g/min) 60 strategies that provide supportive community
OFC
Metabolism
55
activities that engage adolescents in productive
and creative ways. However, as we begin to
50
understand the neurobiological consequences
45 that underlie the adverse environmental fac-
tors that increase the risks for drug use and for
40
addiction, we will be able to develop interven-
35 tions to counteract these changes. Similarly, in
Control Cocaine abuser 1.5 2 2.5 3 3.5 4 4.5
the future, as we gain knowledge of the genes
D2-receptor availability
and the proteins that they encode that make a
Figure 3 | Dopamine D2 receptors and glucose metabolism in addiction. a,b | Positron emission
tomography (PET) images showing dopamine D2 receptors and brain glucose metabolism in the OFC
person more or less vulnerable to taking drugs
(orbitofrontal cortex) in controls and in individuals who abuse cocaine. Note that the individuals abusing and to addiction, more targets will be available
cocaine have reductions in D2 receptors and in OFC metabolism. c | Correlation between measures of D2 to tailor interventions for those at higher risk.
receptors and brain glucose metabolism in the OFC and anterior cingulate gyrus (CG). The lower the D2-
receptor expression, the lower the metabolism in the OFC and CG. Decreased activity in the OFC, a brain Treating addiction. The adaptations in the
region that is implicated in salience attribution and whose disruption results in compulsive behaviour, could brain that result from chronic drug exposure
underlie the compulsive drug administration that occurs in addiction. Decreased activity in the CG, a brain
are long lasting; therefore, addiction must be
region that is involved in inhibitory control, could underlie the inability to restrain from taking the drug when
the addicted person is exposed to them58. viewed as a chronic disease. Long-term treat-
ment will be required for most cases, just as
for other chronic diseases (such as hyperten-
sion, diabetes and asthma)47. This perspective
prevalence of smoking that is initiated after Preventing addiction. The greater vulnerabil- modifies our expectations of treatment and
individuals experience depression could ity of adolescents to experimentation with provides a new understanding of relapse.
reflect, in part, the antidepressant effects of drugs of abuse and to subsequent addiction First, discontinuation of treatment, as for
nicotine as well as the antidepressant effects underscores why prevention of early exposure other chronic diseases, is likely to result in
of monoamine oxidase A and B (MAO-A is such an important strategy to combat drug relapse. Also, as for other chronic medical
and -B) inhibition by cigarette smoke40. On addiction. Epidemiological studies show that conditions, relapse should not be interpreted
the other hand, the reported risk for depres- the prevalence of drug use in adolescents has as a failure of treatment (as is the view in
sion with early drug abuse41 could reflect changed significantly over the past 30 years, most cases of addiction), but instead as a
neuroadaptations in dopamine systems that and some of the decreases seem to be related temporary setback due to lack of compliance
might make individuals more vulnerable to to education about the risks of drugs. For or tolerance to an effective treatment47. Indeed,
depression. example, for marijuana, the prevalence rates the rates of relapse and recovery in the treat-
The higher risk of drug abuse in individ- of use in the United States in 1979 were as ment of drug addiction are equivalent to those
uals with mental illnesses highlights the rele- high as 50%, whereas in 1992 they were as low of other medical diseases47.
vance of the early evaluation and treatment as 20% (REF. 42) (FIG. 4). This changing pattern The involvement of multiple brain circuits
of mental diseases as an effective strategy of marijuana use seems to be related in part to (reward, motivation, learning, inhibitory
to prevent drug addiction that starts as the perception of the risks associated with the control and executive function) and their
self-medication. drug; when adolescents perceived the drug to associated disruption of behaviour indicate
be risky, the rate of use was low, whereas when the need for a multimodal approach in the
Strategies to combat addiction they did not, the rate of use was high (FIG. 4). treatment of the addicted individual. There-
The knowledge of the neurobiology of drugs Similarly, the significant decreases in ecstasy fore, interventions should not be limited to
and the adaptive changes that occur with use as well as cigarette smoking in adolescents inhibiting the rewarding effects of a drug, but
addiction is guiding new strategies for pre- seem to partly reflect effective educational should also include strategies to enhance the
vention and treatment, and identifying areas campaigns43. These results show that, despite saliency value of natural reinforcers (including
in which further research is required. the fact that adolescents are at a stage in their social support), strengthen inhibitory control,
40
would be more effective if complemented with
medications that could help the patient remain
30 drug free.
The participation of the medical com- of personal responsibility in those individuals 1. Volkow, N. D., Fowler, J. S. & Wang, G. J. The addicted
human brain: insights from imaging studies. J. Clin.
munity in many countries, including the who have impairments in these brain circuits? Invest. 111, 1444–1451 (2003).
United States, is further curtailed by the lack This will have implications not only for the 2. Leshner, A. I. Addiction is a brain disease, and it matters.
Science 278, 45–47 (1997).
of reimbursement by most private medical management of drug offenders, but also of 3. Nestler, E. J. Molecular basis of long-term plasticity
insurance policies for the evaluation or other offenders with diagnoses such as antiso- underlying addiction. Nature Rev. Neurosci. 2, 119–128
(2001).
treatment of drug abuse and addiction. This cial personality disorder or conduct disorder. 4. Wagner, F. A. & Anthony, J. C. From first drug use to drug
lack of reimbursement limits the treatment At present, critics of the medical model of dependence: developmental periods of risk for
dependence upon marijuana, cocaine, and alcohol.
infrastructure and the choices that the addiction argue that this model removes the Neuropsychopharmacology 26, 479–488 (2002).
addicted person has with respect to their responsibility of the addicted individual from 5. Spear, L. P. The adolescent brain and age-related
behavioral manifestations. Neurosci. Biobehav. Rev. 24,
treatment. It also sends a negative message his/her behaviour. However, the value of the 417–463 (2000).
to medical students who are interested in medical model of addiction as a public policy 6. Sowell, E. R. et al. Mapping cortical change across the
human life span. Nature Neurosci. 6, 309–315
clinical practice, discouraging them from guide is not to excuse the behaviour of the (2003).
choosing a speciality for which the reim- addicted individual, but to provide a frame- 7. Adriani, W. et al. Evidence for enhanced neurobehavioral
vulnerability to nicotine during periadolescence in rats.
bursement of their services is limited by the work to understand it and to treat it more J. Neurosci. 23, 4712–4716 (2003).
lack of parity. effectively. 8. Kandel, D. B. & Chen, K. Extent of smoking and nicotine
dependence in the United States: 1991–1993. Nicotine.
Another considerable obstacle in the Tob. Res. 2, 263–274 (2000).
treatment of addiction is the limited involve- Summary 9. Slawecki, C. J. & Roth, J. Comparison of the onset of
hypoactivity and anxiety-like behavior during alcohol
ment of the pharmaceutical industry in the Remarkable scientific advances have been withdrawal in adolescent and adult rats. Alcohol Clin.
development of new medications. Issues made in genetics, molecular biology, behav- Exp. Res. 28, 598–607 (2004).
10. Grant, B. F., Stinson, F. S. & Harford, T. C. Age at onset of
such as stigma, lack of reimbursement for ioural neuropharmacology and brain imag- alcohol use and DSM-IV alcohol abuse and dependence:
drug-abuse treatment and the lack of a large ing that offer new insights into how the a 12-year follow-up. J. Subst. Abuse 13, 493–504 (2001).
11. Koob, G. F. & Bloom, F. E. Cellular and molecular
market all contribute to the limited involve- human brain works and moulds behaviour. mechanisms of drug dependence. Science 242,
ment of the pharmaceutical industry in the In the case of addiction, we can now investi- 715–723 (1988).
12. Di Chiara, G. Nucleus accumbens shell and core
development of medications to treat drug gate questions that were previously inaccessi- dopamine: differential role in behavior and addiction.
addiction. The importance of this issue ble, such as how environmental factors and Behav. Brain Res. 137, 75–114 (2002).
13. Wise, R. A. Brain reward circuitry: insights from unsensed
was identified by the Institute of Medicine of genes affect the responses of the brain to incentives. Neuron 36, 229–240 (2002).
the United States, which recommended a drugs and produce neural adaptations that 14. Madras, B. K., Fahey, M. A., Bergman, J., Canfield, D. R.
& Spealman, R. D. Effects of cocaine and related drugs in
programme to provide incentives to the lead to the aberrant behavioural manifesta- nonhuman primates. I. [3H]cocaine binding sites in
pharmaceutical industry as a way of helping tions of addiction. This new knowledge is caudate-putamen. J. Pharmacol. Exp. Ther. 251,
131–141 (1989).
to address this problem56. helping us to understand why drug addicts 15. Kreek, M. J., LaForge, K. S. & Butelman, E.
The translation of scientific findings in relapse even in the face of threats such as Pharmacotherapy of addictions. Nature Rev. Drug
Discov. 1, 710–726 (2002).
drug abuse into prevention and treatment divorce, loss of child custody and incarcera- 16. Schultz, W., Tremblay, L. & Hollerman, J. R. Reward
initiatives clearly requires partnership with tion, even when, in some cases, the drug is no processing in primate orbitofrontal cortex and basal
ganglia. Cereb. Cortex 10, 272–284 (2000).
federal agencies such as the Substance Abuse longer perceived as pleasurable, and is chang- 17. Lu, L., Grimm, J. W., Shaham, Y. & Hope, B. T. Molecular
and Mental Health Services Administration ing how we should approach prevention and neuroadaptations in the accumbens and ventral
tegmental area during the first 90 days of forced
(SAMHSA, which is responsible for U.S. pro- treatment of addiction. abstinence from cocaine self-administration in rats.
grammes to prevent and treat drug abuse) The field is at a crossroads where major J. Neurochem. 85, 1604–1613 (2003).
18. Horvitz, J. C. Mesolimbocortical and nigrostriatal
and the Office of National Drug Control advances in understanding the neuro- dopamine responses to salient non-reward events.
Policy (ONDCP, which is responsible for biology of addiction have helped identify Neuroscience 96, 651–656 (2000).
19. McClure, S. M., Daw, N. D. & Montague, P. R.
U.S. programmes to control availability and promising new medications, but where the A computational substrate for incentive salience. Trends
reduce demand for drugs of abuse). Further- translation of these findings into clinical Neurosci. 26, 423–428 (2003).
20. Schultz, W. Reward signaling by dopamine neurons.
more, improved prevention and treatment practice is limited by several factors, includ- Neuroscientist 7, 293–302 (2001).
programmes could result from collabora- ing the limited involvement of the medical 21. Ito, R., Dalley, J. W., Howes, S. R., Robbins, T. W. &
Everitt, B. J. Dissociation in conditioned dopamine
tions with other agencies and groups, such community in the treatment of addiction, release in the nucleus accumbens core and shell in
as the Department of Education (which can the restricted involvement of the pharma- response to cocaine cues and during cocaine-seeking
behavior in rats. J. Neurosci. 20, 7489–7495 (2000).
bring prevention interventions into the school ceutical industry, the lack of reimbursement 22. Volkow, N. D., Fowler, J. S., Wang, G. J. & Swanson, J. M.
environment), the Department of Justice by private insurance policies and the Dopamine in drug abuse and addiction: results from
imaging studies and treatment implications. Mol.
(which can implement treatment strategies stigma associated with drug addiction. One of Psychiatry 9, 557–569 (2004).
that will minimize the chances of recidivism the main challenges for agencies like the 23. Robinson, T. E., Gorny, G., Mitton, E. & Kolb, B. Cocaine
self-administration alters the morphology of dendrites
and re-incarceration of inmates with National Institute on Drug Abuse (NIDA) and dendritic spines in the nucleus accumbens and
drug-abuse problems) and state and local and the National Institute on Alcohol Abuse neocortex. Synapse 39, 257–266 (2001).
24. Volkow, N. D. & Fowler, J. S. Addiction, a disease of
agencies (which can bring evidence-based and Alcoholism (NIAAA) is to develop compulsion and drive: involvement of the orbitofrontal
and science-based treatments into the knowledge that will help to overcome these cortex. Cereb. Cortex 10, 318–325 (2000).
25. McFarland, K., Davidge, S. B., Lapish, C. C. & Kalivas, P. W.
communities). obstacles. Limbic and motor circuitry underlying footshock-induced
As we learn more about the neurobiology Nora Volkow is at the National Institute on Drug reinstatement of cocaine-seeking behavior. J. Neurosci.
24, 1551–1560 (2004).
of normal and pathological human behav- Abuse, Bethesda, Maryland 20892, USA. 26. Martin-Soelch, C. et al. Changes in reward-induced brain
iour, a challenge for society will be to use this Ting-Kai Li is at the National Institute on Alcohol activation in opiate addicts. Eur. J. Neurosci. 14,
1360–1368 (2001).
knowledge to effectively guide public policy. Abuse and Alcoholism, Bethesda, Maryland 27. Porrino, L. J., Lyons, D., Smith, H. R., Daunais, J. B. &
For example, as we understand the neuro- 20892, USA. Nader, M. A. Cocaine self-administration produces a
progressive involvement of limbic, association, and
biological substrates that underlie voluntary e-mail: nvolkow@nida.nih.gov
sensorimotor striatal domains. J. Neurosci. 24,
actions, how will society define the boundaries doi:1038/nrn1539 3554–3562 (2004).
28. Uhl, G. R. & Grow, R. W. The burden of complex genetics 55. Fielding, J. E., Tye, G., Ogawa, P. L., Imam, I. J. & Long, methoxsalen on nicotine and 4-(methylnitrosamino)-1-
in brain disorders. Arch. Gen. Psychiatry 61, 223–229 A. M. Los Angeles County drug court programs: initial (3-pyridyl)-1-butanone (NNK) metabolism in vivo.
(2004). results. J. Subst. Abuse Treat. 23, 217–224 (2002). Nicotine Tob. Res. 5, 891–899 (2003).
29. Laakso, A., Mohn, A. R., Gainetdinov, R. R. & Caron, M. G. 56. Fulco, C. E., Liverman, C. T. & Earley, L. E. (eds) 71. Kosten, T. R. & Biegel, D. Therapeutic vaccines for
Experimental genetic approaches to addiction. Neuron Development of Medications for the Treatment of Opiate substance dependence. Expert Rev. Vaccines 1,
36, 213–228 (2002). and Cocaine Addictions: Issues for the Government and 363–371 (2002).
30. Chen, C. C. et al. Interaction between the functional Private Sector (Institute of Medicine). (National Academy 72. Krupitsky, E. M. et al. Naltrexone for heroin dependence
polymorphisms of the alcohol-metabolism genes in Press, Washington DC, 1995). treatment in St. Petersburg, Russia. J. Subst. Abuse
protection against alcoholism. Am. J. Hum. Genet. 65, 57. Gfroerer, J. C., Wu, L.-T. & Penne, M. A. Initiation of Treat. 26, 285–294 (2004).
795–807 (1999). marijuana use: trends, patterns and implications. SMA 73. Kampman, K. M. et al. A pilot trial of topiramate for the
31. Rao, Y. et al. Duplications and defects in the CYP2A6 02-3711. Analytic Series A–17. Substance Abuse and treatment of cocaine dependence. Drug Alcohol Depend.
gene: identification, genotyping, and in vivo effects on Mental Health Services Administration, Office of Applied 75, 233–240 (2004).
smoking. Mol. Pharmacol. 58, 747–755 (2000). Studies, Rockville, Maryland (2002). 74. Brodie, J. D., Figueroa, E. & Dewey, S. L. Treating
32. Kathiramalainathan, K. et al. Inhibition of cytochrome 58. Goldstein, R. Z. & Volkow, N. D. Drug addiction and its cocaine addiction: from preclinical to clinical trial
P450 2D6 modifies codeine abuse liability. J. Clin. underlying neurobiological basis: neuroimaging evidence experience with γ-vinyl GABA. Synapse 50, 261–265
Psychopharmacol. 20, 435–444 (2000). for the involvement of the frontal cortex. Am. J. (2003).
33. Dick, D. M. et al. Association of GABRG3 with alcohol Psychiatry 159, 1642–1652 (2002). 75. Raby, W. N. & Coomaraswamy, S. Gabapentin reduces
dependence. Alcohol Clin. Exp. Res. 28, 4–9 (2004). 59. Fowler, J. S. et al. Low monoamine oxidase B in cocaine use among addicts from a community clinic
34. Edenberg, H. J. et al. Variations in GABRA2, encoding peripheral organs in smokers. Proc. Natl Acad. Sci. USA sample. J. Clin. Psychiatry 65, 84–86 (2004).
the α2 subunit of the GABAA receptor, are associated 100, 11600–11605 (2003). 76. Gonzalez, G. et al. Tiagabine increases cocaine-free
with alcohol dependence and with brain oscillations. 60. Anton, R. F. Pharmacologic approaches to the urines in cocaine-dependent methadone-treated
Am. J. Hum. Genet. 74, 705–714 (2004). management of alcoholism. J. Clin. Psychiatry 62 patients: results of a randomized pilot study. Addiction
35. Koob, G. F. Stress, corticotropin-releasing factor, and (Suppl. 20), 11–17 (2001). 98, 1625–1632 (2003).
drug addiction. Ann. NY Acad. Sci. 897, 27–45 (1999). 61. Johnson, B. A. et al. Oral topiramate for treatment of 77. Shoptaw, S. et al. Randomized placebo-controlled trial of
36. Morgan, D. et al. Social dominance in monkeys: alcohol dependence: a randomised controlled trial. baclofen for cocaine dependence: preliminary effects for
dopamine D2 receptors and cocaine self-administration. Lancet 361, 1677–1685 (2003). individuals with chronic patterns of cocaine use. J. Clin.
Nature Neurosci. 5, 169–174 (2002). 62. Salloum, I. M. et al. Efficacy of valproate maintenance in Psychiatry 64, 1440–1448 (2003).
37. Thanos, P. K. et al. Overexpression of dopamine D2 bipolar alcoholics: a double blind placebo controlled 78. Dackis, C. & O’Brien, C. Glutamatergic agents for
receptors reduces alcohol self-administration. study. Arch. Gen. Psychiatry (in the press). cocaine dependence. Ann. NY Acad. Sci. 1003,
J. Neurochem. 78, 1094–1103 (2001). 63. Johnson, B. A. et al. Ondansetron for reduction of 328–345 (2003).
38. Markou, A., Kosten, T. R. & Koob, G. F. Neurobiological drinking among biologically predisposed alcoholic 79. Carroll, K. M. et al. Efficacy of disulfiram and cognitive
similarities in depression and drug dependence: a self- patients: a randomized controlled trial. JAMA 284, behavior therapy in cocaine-dependent outpatients:
medication hypothesis. Neuropsychopharmacology 18, 963–971 (2000). a randomized placebo-controlled trial. Arch. Gen.
135–174 (1998). 64. Mason, B. J., Salvato, F. R., Williams, L. D., Ritvo, E. C. & Psychiatry 61, 264–272 (2004).
39. Grant, B. F. et al. Prevalence and co-occurrence of Cutler, R. B. A double-blind, placebo-controlled study of
substance use disorders and independent mood and oral nalmefene for alcohol dependence. Arch. Gen. Acknowledgments
anxiety disorders: results from the National Epidemiologic Psychiatry 56, 719–724 (1999). The authors thank T. Condon, M. Egli, J. Fowler, C. Kassed,
Survey on Alcohol and Related Conditions. Arch. Gen. 65. Addolorato, G. et al. Baclofen efficacy in reducing alcohol R. Litten, A. Noronha and J. Swanson for thoughtful comments
Psychiatry 61, 807–816 (2004). craving and intake: a preliminary double-blind and editorial assistance.
40. Fowler, J. S., Logan, J., Wang, G. J. & Volkow, N. D. randomized controlled study. Alcohol Alcohol. 37,
Monoamine oxidase and cigarette smoking. 504–508 (2002). Competing interests statement
Neurotoxicology 24, 75–82 (2003). 66. Webster, E. L. et al. In vivo and in vitro characterization of The authors declare no competing financial interests.
41. Brook, D. W., Brook, J. S., Zhang, C., Cohen, P. & antalarmin, a nonpeptide corticotropin-releasing
Whiteman, M. Drug use and the risk of major depressive hormone (CRH) receptor antagonist: suppression of
disorder, alcohol dependence, and substance use pituitary ACTH release and peripheral inflammation. Online links
disorders. Arch. Gen. Psychiatry 59, 1039–1044 (2002). Endocrinology 137, 5747–5750 (1996).
42. Johnston, L. D., O’Malley, P. M. & Bachman, J. G. 67. Fernandez, J. R. & Allison, D. B. Rimonabant Sanofi- FURTHER INFORMATION
Monitoring the future national survey results on drug use, Synthelabo. Curr. Opin. Investig. Drugs 5, 430–435 Encyclopedia of Life Sciences: http://www.els.net/
1975–2002. Volume I: Secondary school students. National (2004). Addiction | Adaptations: meanings | Alcoholism | Cocaine and
Institutes of Health Publication No. 03-5375, (2003). 68. George, T. P. & O’Malley, S. S. Current pharmacological amphetamines | Opiates
43. Johnston, L. D., O’Malley, P. M., Bachman, J. G. & treatments for nicotine dependence. Trends Pharmacol. National Institute on Drug Abuse:
Schulenberg, J. E. Monitoring the future national survey Sci. 25, 42–48 (2004). http://www.drugabuse.gov/NIDAHome.html
results on drug use, 1975–2003. Volume I: Secondary 69. George, T. P. et al. A preliminary placebo-controlled trial Office of National Drug Control Policy:
school students. National Institutes of Health Publication of selegiline hydrochloride for smoking cessation. Biol. http://www.whitehousedrugpolicy.gov/
No. 04-5507, 1–545 (2004). Psychiatry 53, 136–143 (2003). Substance Abuse and Mental Health Services
44. Block, L. G., Morwitz, V. G., Putsis, W. P., Jr & Sen, S. K. 70. Sellers, E. M., Ramamoorthy, Y., Zeman, M. V., Administration: http://www.samhsa.gov/index.aspx
Assessing the impact of antidrug advertising on Djordjevic, M. V. & Tyndale, R. F. The effect of Access to this interactive links box is free online.
adolescent drug consumption: results from a behavioral
economic model. Am. J. Public Health 92, 1346–1351
(2002).
45. Flynn, B. S. et al. Long-term responses of higher and
lower risk youths to smoking prevention interventions. ONLINE CORRESPONDENCE
Prev. Med. 26, 389–394 (1997). Nature Reviews Neuroscience publishes items of correspondence online. Such contributions are published at the discretion of the
46. Gruber, A. J. & Pope, H. G., Jr Marijuana use among Editors and can be subject to peer review. Correspondence should be no longer than 500 words with up to 15 references and
adolescents. Pediatr. Clin. North Am. 49, 389–413 should represent a scholarly attempt to comment on a specific Review or Perspective article that has been published in the
(2002). journal. To view correspondence, please go to our homepage and select the link to New Correspondence, or use the URL
47. McLellan, A. T., Lewis, D. C., O’Brien, C. P. & Kleber, H. D. indicated below.
Drug dependence, a chronic medical illness: implications
for treatment, insurance, and outcomes evaluation. The following correspondence has recently been published:
JAMA 284, 1689–1695 (2000).
48. Schaffer, D. V. & Gage, F. H. Neurogenesis and
Fallacies in behavioural interpretation of auditory cortex plasticity
neuroadaptation. Neuromolecular Med. 5, 1–9 (2004). Ohl, F. and Scheich, H.
49. Kujala, T. et al. Plastic neural changes and reading Reply
improvement caused by audiovisual training in reading- Weinberger, N. M.
impaired children. Proc. Natl Acad. Sci. USA 98,
10509–10514 (2001). Criticisms of ‘Specific long-term memory traces in primary auditory cortex’
50. Fraser, C. et al. Driving plasticity in human adult motor Suga, N., Ji, W. and Ma, X.
cortex is associated with improved motor function after
Reply
brain injury. Neuron 34, 831–840 (2002).
Weinberger, N. M.
51. Kelley, M. S. & Chitwood, D. D. Effects of drug treatment
for heroin sniffers: a protective factor against moving to
http://www.nature.com/nrn/archive/correspondence.html
injection? Soc. Sci. Med. 58, 2083–2092 (2004).
This correspondence relates to the article:
52. Treatment for cocaine use may have HIV benefits. Study
shows how to achieve best results. Aids Alert 18,
118–119 (2003). SPECIFIC LONG-TERM MEMORY TRACES IN PRIMARY AUDITORY
53. Butzin, C. A., Martin, S. S. & Inciardi, J. A. Evaluating
component effects of a prison-based treatment
CORTEX
continuum. J. Subst. Abuse Treat. 22, 63–69 (2002). Weinberger, N. M.
54. Hiller, M. L., Knight, K. & Simpson, D. D. Prison-based Nature Rev. Neurosci. 5, 279–290 (2004).
substance abuse treatment, residential aftercare and
recidivism. Addiction 94, 833–842 (1999).